｜Edited by the Content Team of Zhong Peptide BiochemicalSeptember 25, 2023Day，Novartis Announces Lutathera’s Phase III NETTER-2 Trial Meets Primary Endpoint
Neuroendocrine tumors (NET) are a type of cancer that originates from neuroendocrine cells throughout the body and are generally considered to be slow-growing malignancies. HoweverSome NETs progress rapidly with poor prognosis, and in many cases, they are not diagnosed until the patient's condition has advanced to a late stage. Although NET is a rare disease, its incidence has increased by more than 500% in the past 30 years, creating an urgent need for more treatment options for newly diagnosed patients with inoperable or advanced stages.
NETTER-2 is the second Phase III trial of Lutathera, bringing clinically meaningful results to patients. Lutathera was approved by the FDA for marketing in 2018, primarily based on the pivotal NETTER-1 trial.
About Novartis
Novartis is committed to reimagining medicine to improve people’s quality of life and extend lifespan. By leveraging our technological leadership in research and development, along with innovative accessibility initiatives, we deliver high-value medicines that alleviate the greatest disease burdens on society. In the pursuit of new drugs, we persistently innovate, maintaining a leading position in R&D investment within the global pharmaceutical industry. Novartis has approximately 106,000 employees from over 140 countries and regions worldwide, and nearly 800 million patients globally benefit from Novartis products.
1.Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) | Novartis
